Perceptive Advisors

About The Fund

Perceptive Advisors, established in 1999 and based in New York, New York, is an investment firm that focuses on the life sciences sector. Their investment strategy encompasses deploying capital in a variety of life sciences areas including biotechnology, pharmaceutical, medical device, life science, diagnostics, and health services. They support the advancement of the most promising healthcare innovations, driven by the ambition to back breakthroughs with the potential to transform the world. Perceptive Advisors practices an observant and knowledgeable approach to investments, leveraging their team's expertise in both the scientific and financial aspects of the bio-medical landscape in order to evaluate opportunities from multiple angles. Their process entails a collaborative discovery, where scientific understanding is used to assess the efficacy and impact of innovative healthcare technologies and potential investment opportunities. Moreover, Perceptive Advisors exhibits a strong commitment to fostering innovation by investing across the capital structure in both private and public companies. Their investment portfolio reflects this dedication, featuring companies like 4DMT, which focuses on gene therapy vectors, Achilles Therapeutics in cancer immunotherapy, and AEGEA Medical with vapor ablation technology. With a keen interest in emerging science and technology, the firm is also engaged in diabetes management solutions, targeted cancer immunotherapies, diagnostics, and precision medicine. Perceptive Advisors is not just about funding but also about partnering with companies that offer game-changing contributions to the healthcare sector. With a fund investment minimum of $100,000, a maximum of $10,000,000, and a sweet spot at $1,000,000, they specialize in stages from Pre-Seed to Series A.